We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

396 hedge funds and large institutions have $2.2B invested in CRISPR Therapeutics in 2025 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 123 increasing their positions, 102 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more funds holding in top 10

Funds holding in top 10: 4 → 6 (+2)

27% more call options, than puts

Call options by funds: $96.3M | Put options by funds: $75.6M

21% more repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 102

0.25% less ownership

Funds ownership: 75.64% → 75.39% (-0.25%)

7% less first-time investments, than exits

New positions opened: 55 | Existing positions closed: 59

2% less funds holding

Funds holding: 404 → 396 (-8)

13% less capital invested

Capital invested by funds: $2.54B → $2.2B (-$339M)

Holders
396
Holders Change
-8
Holders Change %
-1.98%
% of All Funds
5.31%
Holding in Top 10
6
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
55
Increased
123
Reduced
102
Closed
59
Calls
$96.3M
Puts
$75.6M
Net Calls
+$20.7M
Net Calls Change
+$30.7M

Top Buyers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
+$53.5M
2
AIM
ARK Investment Management
Florida
+$50.5M
3
Two Sigma Investments
Two Sigma Investments
New York
+$37.4M
4
Morgan Stanley
Morgan Stanley
New York
+$34.1M
5
Two Sigma Advisers
Two Sigma Advisers
New York
+$30.2M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$113M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$34.4M
3
BBA
Baker Bros. Advisors
New York
-$27.7M
4
Citadel Advisors
Citadel Advisors
Florida
-$26.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
RS
326
Rakuten Securities
Japan
$3.23K -$1.06K -25 -21%
CIAM
327
Caitong International Asset Management
Hong Kong
$3.1K -$101K -2,384 -96%
SHIM
328
Stone House Investment Management
Pennsylvania
$3.06K +$3.81K +90 New
BA
329
Bellwether Advisors
Nebraska
$3K – – –
PB
330
Pinnacle Bancorp
Nebraska
$2.93K – – –
WPA
331
West Paces Advisors
Georgia
$2.89K – – –
PK
332
Pflug Koory
Nebraska
$2.86K – – –
PS
333
Principal Securities
Iowa
$2.79K – – –
CWC
334
Carolinas Wealth Consulting
North Carolina
$2.52K +$3.14K +74 New
DWM
335
Dogwood Wealth Management
Kansas
$2.38K – – –
GC
336
Gould Capital
Washington
$2.38K – – –
GWS
337
Greykasell Wealth Strategies
California
$2.31K +$2.88K +68 New
QCG
338
Quadrant Capital Group
Ohio
$2.28K -$1.19K -28 -29%
MSG
339
Main Street Group
Virginia
$2.11K – – –
RIL
340
Rothschild Investment LLC
Illinois
$2.04K – – –
Russell Investments Group
341
Russell Investments Group
United Kingdom
$2.04K +$424 +10 +20%
BIG
342
Brooklyn Investment Group
New York
$2.01K +$2.5K +59 New
IA
343
IFS Advisors
Kansas
$2.01K +$2.5K +59 New
CAL
344
Capital Analysts LLC
Pennsylvania
$2K – – –
OAJ
345
Ogorek Anthony Joseph
New York
$2K – – –
B
346
Birchbrook
Maine
$1.7K – – –
CB
347
Community Bank
New York
$1.7K – – –
MCM
348
MV Capital Management
Maryland
$1.53K +$1.82K +43 +2,150%
AAP
349
Arax Advisory Partners
Colorado
$1.46K +$1.82K +43 New
GSWM
350
Golden State Wealth Management
California
$1.36K – – –
12 13
14
15 16

CRSP Hedge Fund Activity: Q1 2025 in Review

396 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q1 2025, worth a combined $2.2B — down 13% from $2.54B a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of CRSP and 55 opened new positions — a net loss of 4 holders — while 102 trimmed existing stakes and 123 added.

The largest buyer was UBS AM, adding an estimated $53.5M. The largest seller was Capital International Investors, cutting an estimated $113M.

  • 396 institutional investors held CRISPR Therapeutics (CRSP) as of Q1 2025, down from 404 in Q4 2024.
  • Funds reported $2.2B of CRISPR Therapeutics stock for Q1 2025, down 13% quarter-over-quarter.
  • 55 funds opened new CRISPR Therapeutics positions in Q1 2025 and 59 closed out, a net change of -4 holders.
  • The largest CRISPR Therapeutics buyer in Q1 2025 was UBS AM, an estimated $53.5M added.
  • The largest CRISPR Therapeutics seller in Q1 2025 was Capital International Investors, an estimated $113M sold.

Based on aggregated 13F filings for Q1 2025.